Since 2005, Abbott, AstraZeneca and Lilly have collectively received 3 NME approvals (excluding imaging agents), a troublesome performance for companies that have historically made major contributions to innovation.
The top 3 companies, J & J, GSK, and Novartis received 31 approvals during the same period.